Neurology · AnticonvulsantRegulatory Approvalregulatorymid-term

TARO's ANDA219052 for PERAMPANEL Receives Approval Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 6:30:23 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval status for TARO's ANDA219052 for PERAMPANEL is significant as it indicates potential shifts in the anticonvulsant market landscape. This could lead to increased competition, impacting pricing and market share for existing products. Regulatory context from FDA (FDA AP — PERAMPANEL (ORIG)) supports the near-term read. Assessment grounded in 23 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of TARO's approval on market dynamics and consider strategies to maintain competitive advantage. The strongest clinical anchor is Status Epilepticus Population Study (STEPS) (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Anticonvulsant, 6 regulatory and 5 competitive items passed relevance filtering for TARO Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — entity match (neurology). Secondary pressure from [Ad hoc announcement pursuant to Art.. This approval status may enhance TARO's position in the anticonvulsant market, potentially increasing competition against existing branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PERAMPANEL (ORIG) (FDA). Entity match (perampanel); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The approval status indicates that TARO is on track for market entry, which may necessitate adjustments in regulatory strategies for competitors to ensure compliance and maintain market position.

Key Risks

Elevated medium regulatory exposure for TARO Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Status Epilepticus Population Study (STEPS)) could weigh on TARO Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy) could weigh on TARO Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age) could weigh on TARO Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

TARO's entry into the market with PERAMPANEL could disrupt current market dynamics, affecting revenue streams for established competitors and altering market share distributions.
Portfolio teams should assess the impact of TARO's approval on market dynamics and consider strategies to maintain competitive advantage.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval decision and subsequent market entry timelines for TARO's PERAMPANEL.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PERAMPANEL (ORIG)
FDAhigh relevance
Entity match (perampanel); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NGENLA (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Pfizer); Regulatory pathway relevance (nda)
FDA document
View source
Clinical trials for medicines: modifying a clinical trial approval
MHRAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA TA — ANDA219413
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — ANDA220639
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VYEPTI (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Status Epilepticus Population Study (STEPS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ACP-204 in Adults With Alzheimer's Disease Psychosis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Task Sensitivity in Perimenopause and Nutritional Status
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cachexia and Gut Microbiota in Patients With Breast Cancer Receiving Home Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Entity match (neurology)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis
Humanexa Signalshigh relevance
Entity match (neurology)

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

TARO Pharmaceuticals
PERAMPANEL
Epilepsy
Neurology

Commercial impact

medium

TARO's entry into the market with PERAMPANEL could disrupt current market dynamics, affecting revenue streams for established competitors and altering market share distributions.

Regulatory impact

medium

The approval status indicates that TARO is on track for market entry, which may necessitate adjustments in regulatory strategies for competitors to ensure compliance and maintain market position.

What to watch

Monitor for the final approval decision and subsequent market entry timelines for TARO's PERAMPANEL.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.